{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:41:21Z","timestamp":1787002881678,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41375-023-02066-w","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:01:43Z","timestamp":1697263303000},"page":"2339-2342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-9533","authenticated-orcid":false,"given":"Ilaria","family":"Del Giudice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-3026","authenticated-orcid":false,"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2066_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3389\/fonc.2019.00689","volume":"9","author":"I Del Giudice","year":"2019","unstructured":"Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019;9:689.","journal-title":"Front Oncol"},{"key":"2066_CR2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S B\u00f6ttcher","year":"2012","unstructured":"B\u00f6ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980\u20138.","journal-title":"J Clin Oncol"},{"key":"2066_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Tam CS, O\u2019Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303\u20139.","journal-title":"Blood."},{"key":"2066_CR4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","volume":"126","author":"D Rossi","year":"2015","unstructured":"Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921\u20134.","journal-title":"Blood."},{"key":"2066_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hon.3080","volume":"41","author":"R Moia","year":"2023","unstructured":"Moia R, Dondolin R, De Propris MS, Talotta D, Mouhssine S, Perutelli F, et al. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. Hematol Oncol. 2023;41:567\u20130.","journal-title":"Hematol Oncol"},{"key":"2066_CR6","doi-asserted-by":"publisher","first-page":"1130617","DOI":"10.3389\/fonc.2023.1130617","volume":"13","author":"A Fisher","year":"2023","unstructured":"Fisher A, Goradia H, Martinez-Calle N, Patten P, Munir T. The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. Front Oncol. 2023;13:1130617.","journal-title":"Front Oncol"},{"key":"2066_CR7","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1038\/s41375-021-01419-7","volume":"35","author":"S Yang","year":"2021","unstructured":"Yang S, Kay NE, Shi M, Ossenkoppele G, Walter RB, Gale RP. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both? Leukemia. 2021;35:3364\u201370.","journal-title":"Leukemia."},{"key":"2066_CR8","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/blood.2020010146","volume":"138","author":"XV Wang","year":"2021","unstructured":"Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138:2810\u201327.","journal-title":"Blood."},{"key":"2066_CR9","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia. 2022;36:1171\u201375.","journal-title":"Leukemia."},{"key":"2066_CR10","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049\u201360.","journal-title":"J Clin Oncol"},{"key":"2066_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14:2147.","journal-title":"Nat Commun"},{"key":"2066_CR12","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139:3278\u201389.","journal-title":"Blood"},{"key":"2066_CR13","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"2066_CR14","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1200\/JCO.22.02283","volume":"41","author":"T Munir","year":"2023","unstructured":"Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol. 2023;41:3689\u201399.","journal-title":"J Clin Oncol"},{"key":"2066_CR15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388:1739\u201354.","journal-title":"N Engl J Med"},{"key":"2066_CR16","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/blood.2022016901","volume":"140","author":"L Scarf\u00f2","year":"2022","unstructured":"Scarf\u00f2 L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, et al. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R\/R CLL. Blood. 2022;140:2348\u201357.","journal-title":"Blood."},{"key":"2066_CR17","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1038\/s41375-022-01699-7","volume":"36","author":"S Yang","year":"2022","unstructured":"Yang S, Kay NE, Shi M, Hanson CA, Gale RP. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukemia (CLL)? Leukemia. 2022;36:2743\u201347.","journal-title":"Leukemia."},{"key":"2066_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","volume":"35","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021;35:3059\u201372.","journal-title":"Leukemia."},{"key":"2066_CR19","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41375-020-01009-z","volume":"35","author":"R Letestu","year":"2021","unstructured":"Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, et al. French Innovative Leukemia Organization (FILO). Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia. 2021;35:1597\u2013609.","journal-title":"Leukemia."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02066-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02066-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02066-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T09:03:12Z","timestamp":1719478992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02066-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2066"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02066-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}